AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$MDT

KIIL HARRY SKIP sold $139K of MDT

KIIL HARRY SKIP (EVP & President Cardiovascular) sold 1,483 shares of Medtronic plc (MDT) at $93.65 ($0.14M total) on 2026-09-16.

Original reporting
SEC EDGAR · KIIL HARRY SKIP
Published Sep 17, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MDT
Neutral
high confidence
Mentioned
$MDT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDTNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market relevance.

02

Market read

Low relevance; small insider sell unlikely to affect stock price.

03

What to watch

Holding after sale remains 42,186 shares, indicating continued confidence.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑16

Background

Form 4 filings disclose insider transactions; traders monitor for material buys/sells.

Company-level read

Ticker impact

$MDTNeutralHigh confidence
Context

EVP Harry Skip sold 1,483 Medtronic shares for $138,883 on 2026-09-16.

Expected impact

minimal impact, likely negligible price change

Evidence & confidence

Sale size is small relative to market cap; insider is not a major holder.

Market effects

Sector

None; Medtronic operates in medical devices with no sector‑wide impact from this sale.

Regional

None; US‑listed health‑care sector unchanged.

Global

None

Counterpoint

What could challenge this read

Insider sale could signal personal liquidity need, but size is too small to infer company outlook.

Key entities

  • Officer
    Harry Skip

    EVP & President Cardiovascular at Medtronic

  • Company
    Medtronic plc

    Medical device manufacturer (ticker MDT)

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MDT insider trading history →

Related articles

SEP 17
$MDTMed

Medtronic plc (MDT): Other Events

Medtronic plc (MDT) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events On September 14, 2026, Medtronic plc, a public limited company organized under the laws of Ireland (“Medtronic”), commenced an offer to exchange (the “Exchange Offer”) up to 225,361,295 newly issued shares of common stock, par value $0.01 per share (“MiniM

SEC EDGAR 8-K2 min
SEP 17
$MDTHighAI 8/10

Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?

Medtronic (MDT) shares are down 3% this year, but the company's Hugo robotic-assisted surgery system is gaining market share. The FDA approved Hugo for urological procedures, and Medtronic submitted new filings for broader use. Q1 2027 revenue was $9.8B, up 13.7% YoY, with EPS of $1.14, up 40.7%. The company raised full-year guidance and is on track to become a Dividend King. Medtronic's dividend yield is 3.06%, and it is expanding in cardiac and spinal technologies.

fool.com3 min
SEP 17
$MDTMed

Medtronic Sees AI, Ablation and Targeted M&A Fueling Growth

Medtronic (MDT) reported Q1 growth of 7% (excluding an extra week), driven by innovations in cardiac ablation, renal denervation, robotics, and pelvic health. Cardiac ablation revenue surpassed $2B, while pelvic health revenue grew 15%. The company is investing in robotics, structural heart, and neuroscience, and plans to focus on tuck-in acquisitions. Medtronic expects to discuss its growth outlook further at an upcoming Investor Day.

yahoo.com3 min
SEP 17
$MDTHighAI 9/10

FDA clears Medtronic’s LigaSure RAS Maryland device

Medtronic received FDA clearance for its LigaSure RAS Maryland device, compatible with the Hugo robotic-assisted surgery system. The device is designed for vessel sealing in robotic-assisted procedures. Medtronic aims to expand Hugo's use to more soft-tissue surgeries. The device is already available in Europe. Medtronic is working to broaden Hugo's applications in the US, where it is currently approved for urologic procedures.

medicaldevice-network.com2 min